Beta-containing COVID-19 booster vaccine found to cross-neutralize
4.7 (145) · $ 19.99 · In stock
A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.
Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection - ScienceDirect
Frontiers Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
Sanofi-GSK COVID-19 booster could compete against updated Moderna and Pfizer offerings - Drug Discovery and Development
Peptide Products for SARS-CoV-2
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum - ScienceDirect
Frontiers T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets
Dean Huang's Instagram, Twitter & Facebook on IDCrawl
A universal SARS‐CoV DNA vaccine inducing highly cross‐reactive neutralizing antibodies and T cells
